mRNA cancer vaccine combined with Keytruda promising in adjuvant treatment of melanoma
Source: Healio, December 2022
mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, with Keytruda met the primary endpoint of recurrence-free survival in a phase 2b trial for the adjuvant treatment of stage III/IV melanoma after surgical resection.
“This is a pivotal moment because it is really the first vaccine and mRNA technology that has been able to show clinical benefit in a randomized setting against an active comparator,” Michelle Brown, MD, PhD, program director for oncology at Moderna, said in a press conference discussing the results.
“What’s just really fascinating about this treatment is it’s unlike any other treatment that exists today by that it is truly personalized to an individual’s cancer,” Kyle Holen, MD, head of development for oncology at Moderna, said in the press conference.